News

Public · Published

Canaccord Genuity maintains Neurocrine Biosciences at Buy, raises price target to $220 from $210

Canaccord Genuity kept a Buy rating on Neurocrine Biosciences and raised its price target to $220 from $210, a 4.8% increase. The new target implies 51.4% upside from the November 2 close of $145.35.

Published:

Updated:

What happened

Canaccord Genuity kept a Buy rating on Neurocrine Biosciences and raised its price target to $220 from $210, a 4.8% increase. The new target implies 51.4% upside from the November 2 close of $145.35.

Confirmed

Global impact / market context

A higher target from a firm still rated Buy signals the analyst expects more value ahead, which can draw buyer interest in the stock. Because the target sits well above the recent close, it may support holders' confidence and shape expectations.

Analyst inference

Other recent notes carry targets from $150 to $215, so Canaccord's $220 is the highest in that recent set. That gap shows views differ on how much upside exists, even as most recent ratings lean positive.

Analyst inference

What to watch

  1. Watch whether the share price moves toward the $220 target or stays near the $145.35 close, showing how investors weigh the raised target. Confirmed
  2. Watch for further analyst notes on Neurocrine Biosciences that could raise, cut, or repeat targets, since recent targets already span $150 to $215. Proposed
  3. Watch the company's upcoming results and news, because actual profit and sales progress will test whether the 51.4% upside implied by the target holds up. Analyst inference

Evidence

  • Original source link unavailable